Clinical Trials

Study Title

A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain. (M18-969)

Purpose

To assess the safety and efficacy of Elagolix (150 mg QD) when used concurrently with a combined oral contraceptive containing an estrogen and a progesterone in premenopausal women with endometriosis and associated moderate to severe pain.

Eligibility

Study Process